Edition:
United States

Genomic Health Inc (GHDX.OQ)

GHDX.OQ on NASDAQ Stock Exchange Global Select Market

74.22USD
4:00pm EDT
Change (% chg)

$-0.42 (-0.56%)
Prev Close
$74.64
Open
$75.00
Day's High
$75.00
Day's Low
$73.61
Volume
101,795
Avg. Vol
269,157
52-wk High
$91.03
52-wk Low
$50.85

Latest Key Developments (Source: Significant Developments)

Exact Sciences In Advanced Talks To Buy Genomic Health For About $2.8 Bln- Bloomberg
Saturday, 27 Jul 2019 12:47pm EDT 

July 27 (Reuters) - :EXACT SCIENCES CORP IN ADVANCED TALKS TO BUY GENOMIC HEALTH INC FOR ABOUT $2.8 BILLION- BLOOMBERG.  Full Article

Genomic Health and Biocartis expand collaboration to urology with the development of an idylla oncotype dx genomic prostate score test
Monday, 3 Dec 2018 04:51pm EST 

Dec 3 (Reuters) - Biocartis Group NV ::GENOMIC HEALTH AND BIOCARTIS EXPAND COLLABORATION TO UROLOGY WITH THE DEVELOPMENT OF AN IDYLLA ONCOTYPE DX GENOMIC PROSTATE SCORE TEST.GENOMIC HEALTH - AS PART OF AGREEMENT, CO WILL MAKE A PAYMENT OF EUR 2.5 MILLION TO BIOCARTIS, WHICH IS EXPECTED TO BE EXPENSED IN Q4 OF 2018.  Full Article

Genomic Health Reports Q2 Earnings Per Share Of $0.23
Thursday, 2 Aug 2018 04:05pm EDT 

Aug 2 (Reuters) - Genomic Health Inc ::GENOMIC HEALTH ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND REPORTS RECENT BUSINESS PROGRESS.Q2 EARNINGS PER SHARE $0.23.Q2 REVENUE $95.6 MILLION VERSUS I/B/E/S VIEW $92.3 MILLION.Q2 EARNINGS PER SHARE VIEW $0.07 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 REVENUE GROWTH BETWEEN 10% TO 15%.SEES FY 2018 REVENUE BETWEEN $366 MILLION - $382 MILLION .SEES FY 2018 GAAP BASIC EPS BETWEEN $0.00 TO $0.14.SEES FY 2018 NON-GAAP BASIC EPS BETWEEN $0.39 TO $0.56.  Full Article

Genomic Health Q2 Earnings Per Share $0.23
Thursday, 2 Aug 2018 04:05pm EDT 

Genomic Health Inc ::GENOMIC HEALTH ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND REPORTS RECENT BUSINESS PROGRESS.Q2 EARNINGS PER SHARE $0.23.Q2 REVENUE $95.6 MILLION VERSUS I/B/E/S VIEW $92.3 MILLION.Q2 EARNINGS PER SHARE VIEW $0.07 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 REVENUE BETWEEN $366- $382.SEES FY 2018 REVENUE GROWTH BETWEEN 10% TO 15%.SEES FY 2018 GAAP BASIC EPS BETWEEN $0.00 TO $0.14.SEES FY 2018 NON-GAAP BASIC EPS BETWEEN $0.39 TO $0.56.  Full Article

Genomic Health Announces Research Collaboration with Janssen Pharma
Wednesday, 6 Dec 2017 08:00am EST 

Dec 6 (Reuters) - Genomic Health Inc ::GENOMIC HEALTH ANNOUNCES RESEARCH COLLABORATION WITH JANSSEN PHARMACEUTICALS TO EVALUATE THE ONCOTYPE DX® GENOMIC PROSTATE SCORE™ TEST FOR POTENTIAL DRUG DEVELOPMENT.GENOMIC HEALTH - AS PER AGREEMENT, CO WILL TEST SAMPLES FROM JANSSEN STUDIES TO EXAMINE ASSOCIATION OF GENOMIC PROSTATE SCORE RESULTS WITH CLINICAL OUTCOMES.  Full Article

Genomic Health And Cleveland Diagnostics Announce Strategic Collaboration To Develop And Commercialize New Prostate Cancer Tests
Tuesday, 28 Nov 2017 08:00am EST 

Nov 28 (Reuters) - Genomic Health Inc ::GENOMIC HEALTH AND CLEVELAND DIAGNOSTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE NEW PROSTATE CANCER TESTS.GENOMIC HEALTH-DEAL TO PROVIDE CO WITH EXCLUSIVE GLOBAL RIGHTS TO DEVELOP CANCER TESTS BASED ON CLEVELAND DIAGNOSTICS' ISOPSA REAGENT & SIA TECHNOLOGY​.GENOMIC HEALTH INC - ‍GENOMIC HEALTH IS EXPECTED TO BEGIN ADDITIONAL DEVELOPMENT AND CLINICAL VALIDATION OF FIRST HIGH-PSA REFLEX TEST IN 2018​.GENOMIC HEALTH INC - ‍GENOMIC HEALTH WILL MAKE A CONVERTIBLE NOTE INVESTMENT IN CLEVELAND DIAGNOSTICS IN PRINCIPAL AMOUNT OF $2 MILLION IN Q4 OF 2017​.  Full Article

Genomic Health Q3 loss per share $0.06
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - Genomic Health Inc ::Genomic Health announces third quarter 2017 financial results and reports recent business progress.Q3 loss per share $0.06.Q3 revenue $83.8 million versus I/B/E/S view $86.9 million.Q3 earnings per share view $-0.03 -- Thomson Reuters I/B/E/S.Genomic Health - ‍expects to meet low end of FY revenue guidance, which is $345 million, excluding estimated hurricane impact on revenue of about $3 million in Q3​.Genomic Health Inc - ‍expects to deliver full-year profit, excluding $3.2 million cost of biocartis transaction​.  Full Article

Deals of the day-Mergers and acquisitions

July 30 The following bids, mergers, acquisitions and disposals were reported by 2025 GMT on Monday: